181 related articles for article (PubMed ID: 36107670)
21. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
[TBL] [Abstract][Full Text] [Related]
22. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
[TBL] [Abstract][Full Text] [Related]
23. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.
Mason EF; Kuo FC; Hasserjian RP; Seegmiller AC; Pozdnyakova O
Am J Hematol; 2018 Aug; 93(4):504-510. PubMed ID: 29274134
[TBL] [Abstract][Full Text] [Related]
24. Assessing acquired resistance to IDH1 inhibitor therapy by full-exon
Oltvai ZN; Harley SE; Koes D; Michel S; Warlick ED; Nelson AC; Yohe S; Mroz P
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832922
[TBL] [Abstract][Full Text] [Related]
25. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
26. [Isocitrate dehydrogenase gene mutations in acute myeloid leukemia].
Zhou XJ; Zhang SJ; Qiao C; Shen YF; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):902-6. PubMed ID: 21867611
[TBL] [Abstract][Full Text] [Related]
27. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
[TBL] [Abstract][Full Text] [Related]
28. IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype.
Chao HY; Jia ZX; Chen T; Lu XZ; Cen L; Xiao R; Jiang NK; Ying JH; Zhou M; Zhang R
Int J Lab Hematol; 2012 Oct; 34(5):502-9. PubMed ID: 22494415
[TBL] [Abstract][Full Text] [Related]
29. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
30. Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
Koszarska M; Bors A; Feczko A; Meggyesi N; Batai A; Csomor J; Adam E; Kozma A; Orban TI; Lovas N; Sipos A; Karaszi E; Dolgos J; Fekete S; Reichardt J; Lehoczky E; Masszi T; Tordai A; Andrikovics H
Leuk Lymphoma; 2013 May; 54(5):1028-35. PubMed ID: 23039322
[TBL] [Abstract][Full Text] [Related]
31. IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics.
ElNahass YH; Badawy RH; ElRefaey FA; Nooh HA; Ibrahiem D; Nader HA; Mahmoud HK; ElMetnawy WH
Asian Pac J Cancer Prev; 2020 Mar; 21(3):721-725. PubMed ID: 32212799
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
[No Abstract] [Full Text] [Related]
33. High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia.
Ma QL; Wang JH; Wang YG; Hu C; Mu QT; Yu MX; Wang L; Wang DM; Yang M; Yin XF; Chen FF; Lu SS; Chen J; Zhu ZJ; Chen SJ; Jin J
Int J Cancer; 2015 Sep; 137(5):1058-65. PubMed ID: 25523507
[TBL] [Abstract][Full Text] [Related]
34. Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
Ibáñez M; Such E; Cervera J; Luna I; Gómez-Seguí I; López-Pavía M; Dolz S; Barragán E; Fuster O; Llop M; Rodríguez-Veiga R; Avaria A; Oltra S; Senent ML; Moscardó F; Montesinos P; Martínez-Cuadrón D; Martín G; Sanz MA
J Mol Diagn; 2012 Nov; 14(6):594-601. PubMed ID: 22929312
[TBL] [Abstract][Full Text] [Related]
35. Mutation profile of acute myeloid leukaemia in a Chinese cohort by targeted next-generation sequencing.
Lit BMW; Guo BB; Malherbe JAJ; Kwong YL; Erber WN
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1573. PubMed ID: 34617422
[TBL] [Abstract][Full Text] [Related]
36. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
37. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
Duchmann M; Micol JB; Duployez N; Raffoux E; Thomas X; Marolleau JP; Braun T; Adès L; Chantepie S; Lemasle E; Berthon C; Malfuson JV; Pautas C; Lambert J; Boissel N; Celli-Lebras K; Caillot D; Turlure P; Vey N; Pigneux A; Recher C; Terré C; Gardin C; Itzykson R; Preudhomme C; Dombret H; de Botton S
Blood; 2021 May; 137(20):2827-2837. PubMed ID: 33881523
[TBL] [Abstract][Full Text] [Related]
38. [Coexisting Mutations in IDH1/2-Mutated Acute Myeloid Leukemia].
Jia ZX; Chao HY; Liu J; Cai XH; Qin W; Wu P; Lu XZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1440-1448. PubMed ID: 31607296
[TBL] [Abstract][Full Text] [Related]
39. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Borate U; Yang F; Press R; Ruppert AS; Jones D; Caruthers S; Zhao W; Vergilio JA; Pavlick DC; Juckett L; Norris B; Bucy T; Burd A; Stein EM; Patel P; Baer MR; Stock W; Schiller G; Blum W; Kovacsovics T; Litzow M; Foran J; Heerema NA; Rosenberg L; Marcus S; Yocum A; Stefanos M; Druker B; Byrd JC; Levine RL; Mims A
Blood Adv; 2023 Oct; 7(20):6048-6054. PubMed ID: 37459200
[TBL] [Abstract][Full Text] [Related]
40. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
Zhou KG; Jiang LJ; Shang Z; Wang J; Huang L; Zhou JF
Leuk Lymphoma; 2012 Dec; 53(12):2423-9. PubMed ID: 22616558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
